<p>喬治亞州的一名聯邦法官週一 reportedly 拒絕了 <strong>Teva Pharmaceutical Industries Ltd.</strong> (NYSE: TEVA) 延遲數千起訴訟中首場審判的請求，這些訴訟指控其 Paragard 宮內節育器 (IUD) 在移除時可能會斷裂。</p>
<p>Paragard 是一種非激素的避孕裝置，由銅製成，可以植入多年。</p>
<p>負責監督合併聯邦訴訟的美國地區法官 <strong>Leigh Martin May</strong> 週一裁定，審判應按計劃於 1 月 20 日進行。</p>
<p>該公司曾請求法院暫停案件，等待對早前拒絕 Teva 試圖駁回訴訟的決定的上訴。</p>
<p>Teva 辯稱，成功的上訴可能會完全結束訴訟，而該訴訟包括約 3800 起集中在聯邦法院的訴訟。原告反駁稱，該請求主要是拖延戰術，會不必要地延緩案件的進展。</p>
<p>即將進行的審判將作為多區訴訟中的首個 “風向標” 審判，路透社報道。</p>
<p>在 11 月，Teva 和 <strong>The Cooper Companies</strong> (NASDAQ: COO) 在喬治亞州聯邦法院尋求 簡易判決，與 Paragard IUD 相關的多區訴訟的風向標審判，原告聲稱該裝置可能在子宮內斷裂，可能導致傷害、生育併發症和需要外科干預。</p>
<p>這些公司辯稱，美國食品藥品監督管理局 (FDA) 的批准優先於與該裝置設計和警告標籤相關的州法律索賠，聲稱原告提出的任何更改都與 FDA 批准的規格相沖突。</p>
<p>Teva 和 Cooper 認為，雖然在出現新信息時允許進行設計修改，但 Paragard 的斷裂風險早已為人所知，並不符合該標準。他們堅持認為，所稱缺陷並不證明在沒有 FDA 授權的情況下進行單方面更改是合理的。</p>
<p>然而，美國地區法官 <strong>Leigh Martin May</strong> 對原告聲稱 Teva 花了五年時間才遵守 2010 年發佈的 FDA 指令以更新 Paragard 警告標籤表示擔憂。May 法官指出，這一延遲似乎是故意的，並暗示 Teva 可能試圖依賴自身的不合規來支持其優先權辯護。</p>
<p>Teva 開發了這種基於銅的裝置，但在 2017 年將其出售給 Cooper Companies。May 法官之前允許原告 <strong>Pauline Rickard</strong>、<strong>Alisa Robere</strong> 和 <strong>Melody Braxton</strong> 的索賠進入風向標審判。</p>
<p>Cooper 在 2025 年 11 月單獨辯稱，應該將其從風向標審判中駁回，稱其在原告收到裝置後才收購 Paragard。</p>
<p>Teva 於 2017 年將 Paragard 產品出售給 CooperSurgical。對 CooperSurgical 在 Rickard 案件中的索賠被單獨駁回。Teva 仍然是那些在公司擁有該產品期間收到該裝置的患者的被告。</p>
<p>路透社指出，在 12 月的裁決中，May 法官駁回了 Teva 的論點，稱聯邦法律禁止這些索賠，因為公司在沒有 FDA 批准的情況下無法更改 Paragard 的警告標籤。</p>
<p>法官發現證據表明 Teva 收到了可能支持標籤更新的新安全信息，無論患者何時收到該裝置。</p>
<p><strong>價格動態</strong>：在週二的盤前交易中，TEVA 股票下跌 0.21%，報 32.72 美元。</p>
<p><em>圖片來源：Shutterstock</em></p>

梯瓦制藥

<p>一名聯邦法官拒絕了梯瓦製藥（Teva Pharmaceutical Industries）推遲與其 Paragard 宮內節育器相關的首次審判的請求，該審判定於 1 月 20 日開始。此次審判是涉及約 3,800 起訴訟的更大訴訟的一部分，這些訴訟指控該設備在移除時可能會斷裂，導致受傷。梯瓦辯稱，上訴可能會結束訴訟，但法官裁定審判應繼續進行。關於梯瓦是否遵守 FDA 關於警告標籤的要求也引發了擔憂。梯瓦的股票在盤前交易中下跌 0.21%，報 32.72 美元</p>

<p>A Georgia federal judge on Monday reportedly denied <strong>Teva Pharmaceutical Industries Ltd.</strong> (NYSE: TEVA) a request to delay the first trial in thousands of lawsuits alleging its Paragard intrauterine device (IUD) can fracture during removal.</p>
<div class="lb-trans"><p>喬治亞州的一名聯邦法官週一 reportedly 拒絕了 <strong>Teva Pharmaceutical Industries Ltd.</strong> (NYSE: TEVA) 延遲數千起訴訟中首場審判的請求，這些訴訟指控其 Paragard 宮內節育器 (IUD) 在移除時可能會斷裂。</p>
</div><p>Paragard is a non-hormonal contraceptive device made of copper that can remain implanted for years.</p>
<div class="lb-trans"><p>Paragard 是一種非激素的避孕裝置，由銅製成，可以植入多年。</p>
</div><p>U.S. District Judge <strong>Leigh Martin May</strong>, who is overseeing the consolidated federal litigation, ruled Monday that the trial should proceed as scheduled on January 20.</p>
<div class="lb-trans"><p>負責監督合併聯邦訴訟的美國地區法官 <strong>Leigh Martin May</strong> 週一裁定，審判應按計劃於 1 月 20 日進行。</p>
</div><p>The company had asked the court to pause the case while it appealed an earlier decision rejecting Teva's attempt to have the claims dismissed.</p>
<div class="lb-trans"><p>該公司曾請求法院暫停案件，等待對早前拒絕 Teva 試圖駁回訴訟的決定的上訴。</p>
</div><p>Teva argued that a successful appeal could have ended the litigation entirely, which includes about 3,800 lawsuits centralized in federal court. Plaintiffs countered that the request was primarily a delay tactic and would unnecessarily stall progress in the case.</p>
<div class="lb-trans"><p>Teva 辯稱，成功的上訴可能會完全結束訴訟，而該訴訟包括約 3800 起集中在聯邦法院的訴訟。原告反駁稱，該請求主要是拖延戰術，會不必要地延緩案件的進展。</p>
</div><p>The upcoming trial will serve as the first &#34;bellwether&#34; in the multi-district litigation, Reuters reported.</p>
<div class="lb-trans"><p>即將進行的審判將作為多區訴訟中的首個 “風向標” 審判，路透社報道。</p>
</div><p>In November, Teva and <strong>The Cooper Companies</strong> (NASDAQ: COO) sought summary judgment ahead of bellwether trials in the Georgia federal court related to multidistrict litigation over the Paragard IUD, which plaintiffs allege can break inside the uterus, potentially causing injuries, fertility complications, and the need for surgical intervention.</p>
<div class="lb-trans"><p>在 11 月，Teva 和 <strong>The Cooper Companies</strong> (NASDAQ: COO) 在喬治亞州聯邦法院尋求 簡易判決，與 Paragard IUD 相關的多區訴訟的風向標審判，原告聲稱該裝置可能在子宮內斷裂，可能導致傷害、生育併發症和需要外科干預。</p>
</div><p>The companies argue that U.S. Food and Drug Administration (FDA) approval preempts state-law claims related to the device's design and warning labels, asserting that any changes proposed by plaintiffs would have conflicted with FDA-approved specifications.</p>
<div class="lb-trans"><p>這些公司辯稱，美國食品藥品監督管理局 (FDA) 的批准優先於與該裝置設計和警告標籤相關的州法律索賠，聲稱原告提出的任何更改都與 FDA 批准的規格相沖突。</p>
</div><p>Teva and Cooper contend that while design modifications are allowed when new information emerges, Paragard's risk of breakage has long been known and does not meet that threshold. They maintain that the alleged defects do not justify unilateral changes without FDA authorization.</p>
<div class="lb-trans"><p>Teva 和 Cooper 認為，雖然在出現新信息時允許進行設計修改，但 Paragard 的斷裂風險早已為人所知，並不符合該標準。他們堅持認為，所稱缺陷並不證明在沒有 FDA 授權的情況下進行單方面更改是合理的。</p>
</div><p>U.S. District Judge <strong>Leigh Martin May</strong>, however, expressed concern over plaintiffs' claims that Teva took five years to comply with an FDA mandate issued in 2010 to update Paragard's warning labels. Judge May indicated the delay appeared intentional and suggested Teva may be attempting to rely on its own noncompliance to support its preemption defense.</p>
<div class="lb-trans"><p>然而，美國地區法官 <strong>Leigh Martin May</strong> 對原告聲稱 Teva 花了五年時間才遵守 2010 年發佈的 FDA 指令以更新 Paragard 警告標籤表示擔憂。May 法官指出，這一延遲似乎是故意的，並暗示 Teva 可能試圖依賴自身的不合規來支持其優先權辯護。</p>
</div><p>Teva developed the copper-based device but sold it to Cooper Companies in 2017. Judge May previously allowed claims from plaintiffs <strong>Pauline Rickard</strong>, <strong>Alisa Robere</strong>, and <strong>Melody Braxton</strong> to proceed to bellwether trials.</p>
<div class="lb-trans"><p>Teva 開發了這種基於銅的裝置，但在 2017 年將其出售給 Cooper Companies。May 法官之前允許原告 <strong>Pauline Rickard</strong>、<strong>Alisa Robere</strong> 和 <strong>Melody Braxton</strong> 的索賠進入風向標審判。</p>
</div><p>Cooper, in November 2025, separately argues it should be dismissed from the bellwether trials, stating it acquired Paragard after the plaintiffs received their devices.</p>
<div class="lb-trans"><p>Cooper 在 2025 年 11 月單獨辯稱，應該將其從風向標審判中駁回，稱其在原告收到裝置後才收購 Paragard。</p>
</div><p>Teva sold the Paragard product to CooperSurgical in 2017. Claims against CooperSurgical in Rickard's case were dismissed separately. Teva remains a defendant for patients who received the device while the company owned the product.</p>
<div class="lb-trans"><p>Teva 於 2017 年將 Paragard 產品出售給 CooperSurgical。對 CooperSurgical 在 Rickard 案件中的索賠被單獨駁回。Teva 仍然是那些在公司擁有該產品期間收到該裝置的患者的被告。</p>
</div><p>Reuters noted that in a December ruling, May rejected Teva's argument that federal law barred the claims because the company could not change Paragard's warning label without FDA approval.</p>
<div class="lb-trans"><p>路透社指出，在 12 月的裁決中，May 法官駁回了 Teva 的論點，稱聯邦法律禁止這些索賠，因為公司在沒有 FDA 批准的情況下無法更改 Paragard 的警告標籤。</p>
</div><p>The judge found evidence suggesting Teva had received new safety information that could have supported a label update, regardless of when patients received the device.</p>
<div class="lb-trans"><p>法官發現證據表明 Teva 收到了可能支持標籤更新的新安全信息，無論患者何時收到該裝置。</p>
</div><p><strong>Price Action</strong>: TEVA stock is down 0.21% at $32.72 during the premarket session at the last check on Tuesday.</p>
<div class="lb-trans"><p><strong>價格動態</strong>：在週二的盤前交易中，TEVA 股票下跌 0.21%，報 32.72 美元。</p>
</div><p><em>Image: Shutterstock</em></p>
<div class="lb-trans"><p><em>圖片來源：Shutterstock</em></p>
</div>

法官駁回了梯瓦製藥暫停 Paragard 銅避孕設備訴訟審判的申請